Roche and Lilly team up to detect early signs of Alzheimer’s

CAR-T Digest - August 2020

Weekly Digest - 18-24 Mar 2023

March 22, 2023: Elecsys (Elecsys Amyloid Plasma Panel) / Alzheimer’s disease / Roche / Lilly: Collaboration to enhance the early detection of Alzheimer’s disease

Eli Lilly and Roche are working together to assist the development of the Elecsys Amyloid Plasma Panel (EAPP), which can identify early indications of Alzheimer’s disease and assess whether a patient needs further confirmation
- Roche’s Elecsys Amyloid Plasma Panel (EAPP) measures phosphorylated Tau (pTau) 181 protein assay and apolipoprotein (APOE) E4 assay in human blood plasma
- In July 2022 FDA granted breakthrough device designation for EAPP
If approved, the EAPP test would be an added tool for identifying symptomatic patients with a low likelihood of amyloid pathology
This approval will enable Roche and Lilly with another tool for entering the Alzheimer’s market